BiTE免疫疗法-话题@MedSci

#BiTE免疫疗法#

6篇内容 | 364人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1780354, encodeId=f41c1e8035409, content=<a href='/topic/show?id=db57349347' target=_blank style='color:#2F92EE;'>#BiTE免疫疗法#</a>, objectTitle=安进BiTE免疫疗法疗效惊人：完全缓解率近100%, objectType=article, longId=157075, objectId=456e15e075e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456e15e075e2, replyNumber=0, likeNumber=35, createdTime=2019-04-02, rootId=0, userName=124987e8m07暂无昵称, userId=101c2500074, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456e15e075e2, moduleTitle=安进BiTE免疫疗法疗效惊人：完全缓解率近100%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=456e15e075e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780353, encodeId=ea721e8035336, content=<a href='/topic/show?id=db57349347' target=_blank style='color:#2F92EE;'>#BiTE免疫疗法#</a>, objectTitle=喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）, objectType=article, longId=76569, objectId=1570e65698b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1570e65698b, replyNumber=0, likeNumber=42, createdTime=2017-04-24, rootId=0, userName=124987e8m07暂无昵称, userId=101c2500074, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1570e65698b, moduleTitle=喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1570e65698b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780352, encodeId=e0941e803523d, content=<a href='/topic/show?id=db57349347' target=_blank style='color:#2F92EE;'>#BiTE免疫疗法#</a>, objectTitle=FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格, objectType=article, longId=67544, objectId=c7dd6e544b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7dd6e544b6, replyNumber=0, likeNumber=37, createdTime=2016-12-01, rootId=0, userName=124987e8m07暂无昵称, userId=101c2500074, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7dd6e544b6, moduleTitle=FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7dd6e544b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780351, encodeId=989c1e803510f, content=<a href='/topic/show?id=db57349347' target=_blank style='color:#2F92EE;'>#BiTE免疫疗法#</a>, objectTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, objectType=article, longId=63534, objectId=bde06353427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde06353427, replyNumber=0, likeNumber=33, createdTime=2016-09-30, rootId=0, userName=124987e8m07暂无昵称, userId=101c2500074, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde06353427, moduleTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bde06353427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780350, encodeId=2b1d1e8035016, content=<a href='/topic/show?id=db57349347' target=_blank style='color:#2F92EE;'>#BiTE免疫疗法#</a>, objectTitle=ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）, objectType=article, longId=43800, objectId=5ccf43800e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ccf43800e2, replyNumber=0, likeNumber=57, createdTime=2015-07-12, rootId=0, userName=124987e8m07暂无昵称, userId=101c2500074, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ccf43800e2, moduleTitle=ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ccf43800e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780349, encodeId=884b1e8034925, content=<a href='/topic/show?id=db57349347' target=_blank style='color:#2F92EE;'>#BiTE免疫疗法#</a>, objectTitle=安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请, objectType=article, longId=40707, objectId=85ed40e07b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ed40e07b0, replyNumber=0, likeNumber=36, createdTime=2015-04-10, rootId=0, userName=124987e8m07暂无昵称, userId=101c2500074, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ed40e07b0, moduleTitle=安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ed40e07b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BiTE免疫疗法

2020-05-29

124987e8m07暂无昵称 (审核中...)

前往app查看评论内容

#BiTE免疫疗法#

安进BiTE免疫疗法疗效惊人：完全缓解率近100%

2019-04-02

124987e8m07暂无昵称 (审核中...)

前往app查看评论内容

#BiTE免疫疗法#

喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）

2017-04-24

124987e8m07暂无昵称 (审核中...)

前往app查看评论内容

#BiTE免疫疗法#

FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格

2016-12-01

124987e8m07暂无昵称 (审核中...)

前往app查看评论内容

#BiTE免疫疗法#

BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功

2016-09-30

124987e8m07暂无昵称 (审核中...)

前往app查看评论内容

#BiTE免疫疗法#

ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）

2015-07-12

124987e8m07暂无昵称 (审核中...)

前往app查看评论内容

#BiTE免疫疗法#

安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请

2015-04-10

科室
- - 订阅+
  - 更多科室
工具
服务